Attovia Therapeutics, Inc. ATTO
16.73 USD 0.00 (+0.00%)
At closeNov 11, 2026, 4:00 PM EST
16.73 0.00 0.00%
After hours · Nov 11, 4:00 PM ET
Day range unavailable
12.94 52-week range 28.00
- YTD
- -23.61%
- 1 year
- -23.61%
News
benzinga.com Citigroup Maintains Buy on Attovia Therapeutics, Raises Price Target to $34 Citigroup analyst Yigal Nochomovitz maintains Attovia Therapeutics (NASDAQ:ATTO) with a Buy and raises the price target from $30 to $34.
benzinga.com Morgan Stanley Maintains Overweight on Attovia Therapeutics, Raises Price Target to $40 Morgan Stanley analyst Judah Frommer maintains Attovia Therapeutics (NASDAQ:ATTO) with a Overweight and raises the price target from $39 to $40.
seekingalpha.com Attovia Therapeutics, Inc. (ATTO) Discusses ATTO-1310 Phase Ib Results in Chronic Pruritus and Atopic Dermatitis Transcript Attovia Therapeutics, Inc. (ATTO) Discusses ATTO-1310 Phase Ib Results in Chronic Pruritus and Atopic Dermatitis Transcript
benzinga.com Attovia Therapeutics Q3 EPS $(0.76) Misses $(0.50) Estimate Attovia Therapeutics (NASDAQ:ATTO) reported quarterly losses of $(0.76) per share which missed the analyst consensus estimate of $(0.50) by 52 percent. This is a 77.91 percent increase over losses of…
globenewswire.com Attovia Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update Announced positive topline 12-week Phase 1b results for ATTO-1310 in patients with chronic pruritus (CP) and high-itch atopic dermatitis (AD) Initiation of global Phase 2 trials of ATTO-1310 in…
marketbeat.com Attovia Therapeutics Reports Sustained Itch Relief in Small Study, Plans Phase 2 Trials Attovia Therapeutics NASDAQ: ATTO reported 12-week results from a small phase 1b study of its experimental itch treatment ATTO-1310, saying a single dose produced sustained responses in patients with…
globenewswire.com Attovia Therapeutics Announces Positive Topline 12-Week Results from Phase 1b Study of ATTO-1310 in Patients with Chronic Pruritus and High-Itch Atopic Dermatitis Results build on preliminary Week 4 findings, in which a single dose of ATTO-1310 demonstrated rapid, deep, and durable itch relief in patients with chronic pruritus (CP) and high-itch atopic…- benzinga.com Attovia Therapeutics To Present New Clinical, Translational, And Preclinical Data Across Its Pipeline At EADV Congress And FCD 2026 Attovia Therapeutics, Inc. ("Attovia") (NASDAQ:ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today…
benzinga.com Quanex Building Products, Concrete Pumping, SanDisk And Other Big Stocks Moving Higher On Friday U.S. stocks mostly fell, but Quanex surged 16.6% after beating earnings and sales estimates; Reading, BBCP, Astera Labs and others also gained.
benzinga.com Attovia Therapeutics Q2 EPS $(4.88) Misses $(4.62) Estimate, Sales $450.000K Attovia Therapeutics (NASDAQ:ATTO) reported quarterly losses of $(4.88) per share which missed the analyst consensus estimate of $(4.62) by 5.63 percent. This is a 31.54 percent decrease over losses…- benzinga.com Citigroup Initiates Coverage On Attovia Therapeutics with Buy Rating, Announces Price Target of $30 Citigroup analyst Yigal Nochomovitz initiates coverage on Attovia Therapeutics (NASDAQ:ATTO) with a Buy rating and announces Price Target of $30.
benzinga.com LifeSci Capital Initiates Coverage On Attovia Therapeutics with Outperform Rating, Announces Price Target of $45 LifeSci Capital initiates coverage on Attovia Therapeutics (NASDAQ:ATTO) with a Outperform rating and announces Price Target of $45.- benzinga.com Leerink Partners Initiates Coverage On Attovia Therapeutics with Outperform Rating, Announces Price Target of $52 Leerink Partners analyst Thomas Smith initiates coverage on Attovia Therapeutics (NASDAQ:ATTO) with a Outperform rating and announces Price Target of $52.
benzinga.com RBC Capital Initiates Coverage On Attovia Therapeutics with Outperform Rating, Announces Price Target of $45 RBC Capital analyst Brian Abrahams initiates coverage on Attovia Therapeutics (NASDAQ:ATTO) with a Outperform rating and announces Price Target of $45.
benzinga.com This Lumentum Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
benzinga.com Morgan Stanley Initiates Coverage On Attovia Therapeutics with Overweight Rating, Announces Price Target of $39 Morgan Stanley analyst Judah Frommer initiates coverage on Attovia Therapeutics (NASDAQ:ATTO) with a Overweight rating and announces Price Target of $39.
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Aethlon Medical (NASDAQ:AEMD) stock rose 50.7% to $3.27 during Thursday's after-market session. The market value of their outstanding shares is at $1.6 million. Modular Medical (NASDAQ:MODD)…
benzinga.com Stocks That Hit 52-Week Lows On Thursday Thursday's session saw 189 companies set new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Friday Friday's session saw 100 companies set new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Tuesday Tuesday's morning session saw 84 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 497 companies set new 52-week lows.
- benzinga.com Why Foresight Autonomous Shares Jumped 33%; Here Are 83 Biggest Movers From Yesterday Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares surged 106.3% to close at $0.21 on Wednesday after dipping around 48% on Tuesday. Fast Radius established a timeline for a Chapter 11 sale process.
- benzinga.com Why Target Shares Are Trading Lower By 14%? Here Are 56 Stocks Moving In Wednesday's Mid-Day Session Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares jumped 109% to $0.2115 after dipping around 48% on Tuesday. Fast Radius established a timeline for a Chapter 11 sale process.
- benzinga.com Earnings Scheduled For November 15, 2022 Companies Reporting Before The Bell • Alkaline Water Co (NASDAQ:WTER) is likely to report quarterly loss at $0.05 per share on revenue of $18.31 million.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 507 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 191 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 49 companies reached new 52-week lows.
- benzinga.com Earnings Scheduled For August 3, 2022 Companies Reporting Before The Bell • Fresh Del Monte Produce (NYSE:FDP) is likely to report quarterly earnings at $0.79 per share on revenue of $1.15 billion.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 550 companies achieved new lows for the year.
benzinga.com 71 Biggest Movers From Yesterday Gainers CynergisTek, Inc. (NYSE: CTEK) shares surged 100% to close at $1.18 on Tuesday after the company entered into a definitive agreement to be acquired by Clearwater Compliance for roughly $17.7…- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 540 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 153 companies set new 52-week lows.
- benzinga.com Earnings Scheduled For May 11, 2022 Companies Reporting Before The Bell • Great Elm Capital (NASDAQ:GECC) is expected to report earnings for its first quarter.
- benzinga.com Earnings Scheduled For April 27, 2022 Companies Reporting Before The Bell • Deutsche Bank (NYSE:DB) is projected to report earnings for its first quarter.
- benzinga.com 96 Biggest Movers From Yesterday Gainers Volt Information Sciences, Inc. (NYSE: VOLT) shares surged 94.7% to close at $5.88 on Monday after the company announced it would be acquired for $6 per share.
- benzinga.com Earnings Scheduled For November 15, 2021 Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is estimated to report earnings for its third quarter.
- benzinga.com Earnings Scheduled For August 4, 2021 Companies Reporting Before The Bell • UroGen Pharma (NASDAQ:URGN) is projected to report earnings for its second quarter.
- benzinga.com Stocks That Hit 52-Week Highs On Wednesday Before 10 a.m. ET Wednesday, 138 stocks hit new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Tuesday During Tuesday's morning session, 124 stocks hit new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Thursday This morning 158 companies set new 52-week highs.
- benzinga.com Earnings Scheduled For May 5, 2021 Companies Reporting Before The Bell • Monmouth Real Estate (NYSE:MNR) is likely to report earnings for its second quarter.
- benzinga.com Earnings Scheduled For March 3, 2021 Companies Reporting Before The Bell • Brown Forman Inc Class A Common Stock (NYSE:BF) is likely to report earnings for its third quarter.
- benzinga.com Stocks That Hit 52-Week Highs On Thursday Before 10 a.m. ET on Thursday, 394 companies hit new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Wednesday This morning 533 companies reached new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Tuesday On Tuesday, 596 companies set new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Thursday During Thursday's morning session, 255 companies made new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Wednesday Before 10 a.m. ET on Wednesday, 192 companies set new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Tuesday On Tuesday morning, 172 companies achieved new highs for the year.
- benzinga.com Stocks That Hit 52-Week Highs On Friday During the morning session on Friday, 156 stocks hit new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Thursday Thursday's morning session saw 73 companies set new 52-week highs.